Automate Your Wheel Strategy on VKTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VKTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VKTX
- Rev/Share 0.0
- Book/Share 7.5571
- PB 3.6403
- Debt/Equity 0.0012
- CurrentRatio 44.2458
- ROIC -0.2032
- MktCap 3089648100.0
- FreeCF/Share -1.1956
- PFCF -23.0593
- PE -24.0418
- Debt/Assets 0.0012
- DivYield 0
- ROE -0.1441
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VKTX | Cantor Fitzgerald | -- | Overweight | -- | $104 | April 29, 2025 |
| Initiation | VKTX | Goldman | -- | Neutral | -- | $30 | April 8, 2025 |
| Initiation | VKTX | Scotiabank | -- | Sector Outperform | -- | $102 | Feb. 13, 2025 |
| Initiation | VKTX | Citigroup | -- | Neutral | -- | $38 | Feb. 7, 2025 |
| Initiation | VKTX | JP Morgan | -- | Overweight | -- | $80 | Sept. 11, 2024 |
News
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled.
Published: March 11, 2025 by: Investors Business Daily
Sentiment: Negative
Viking Therapeutics stock toppled Tuesday after the biotech company inked a $150 million manufacturing deal for its weight-loss drug, VK2735. The post Viking Therapeutics Just Inked A $150 Million Manufacturing Deal.
Read More
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Published: February 28, 2025 by: The Motley Fool
Sentiment: Positive
Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth and stock performance.
Read More
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Published: February 26, 2025 by: MarketBeat
Sentiment: Neutral
The GLP-1 industry is currently an oligopoly ruled by two pharmaceutical giants, Novo Nordisk A/S NYSE: NVO, maker of semaglutide under the Ozempic and Wegovy name brands, and Eli Lilly & Co. NYSE: LLY, maker of tirzepatide and dual GLP-1/GIP agonist treatment sold under Mounjaro and Zepbound name brands. As compounding facilities cease making compounded versions of their drugs, which are no longer on the FDA drug shortage list, the medical sector oligopoly will likely regain many more users to seal their dominance.
Read More
Is Viking Therapeutics a Buy Right Now?
Published: February 26, 2025 by: The Motley Fool
Sentiment: Positive
Viking Therapeutics (VKTX -3.01%) soared into the spotlight about a year ago when it delivered promising data on a drug candidate that aims to compete in an area of very high demand: weight loss. The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.
Read More
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Read More
Should You Buy VKTX Stock Amid Renewed M&A Speculations?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.
Read More
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Published: February 24, 2025 by: The Motley Fool
Sentiment: Positive
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%.
Read More
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.
Read More
About Viking Therapeutics, Inc. (VKTX)
- IPO Date 2015-04-28
- Website https://www.vikingtherapeutics.com
- Industry Biotechnology
- CEO Brian Lian
- Employees 45